NCT04137185View on ClinicalTrials.gov

Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 10, 2019

Primary Completion Date

December 29, 2020

Study Completion Date

December 29, 2020

Conditions
Differentiated Thyroid Cancer
Interventions
DRUG

Recombinant Human Thyroid Stimulating Hormone for Injection

rhTSH was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04137185 - Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients | Biotech Hunter | Biotech Hunter